Coast J, Smith R D, Millar M R
Department of Social Medicine, University of Bristol, UK.
Health Econ. 1996 May-Jun;5(3):217-26. doi: 10.1002/(SICI)1099-1050(199605)5:3<217::AID-HEC200>3.0.CO;2-S.
This paper argues that increasing resistance to antimicrobials is an important social externality that has not been captured at the level of economic appraisal. The paper explicitly considers reasons why the externality of antimicrobial resistance has not generally been included as a cost in economic evaluations comparing management strategies for infectious diseases. Four reasons are considered: first, that the absolute cost of antimicrobial resistance is too small to be worth including; second, that there is an implicit discounting of the costs of antimicrobial resistance on the basis of time preference which makes the cost too small to be worth including; third, that there is an implicit discounting of the costs of antimicrobial resistance on the basis of uncertainty which makes the cost too small to be worth including; and fourth, that the costs are too difficult to measure. Although there does not appear to be methodological justification for excluding the costs of antimicrobial resistance, it seems likely that, because of the practical difficulties associated with measuring these costs, they will continue to be ignored. The paper concludes with a discussion of the applicability of standard policy responses used to deal with externalities in other areas of welfare economics.
本文认为,抗菌药物耐药性的不断增加是一个重要的社会外部效应,在经济评估层面尚未得到考量。本文明确探讨了抗菌药物耐药性的外部效应为何在比较传染病管理策略的经济评估中通常未被纳入成本的原因。考虑了四个原因:第一,抗菌药物耐药性的绝对成本过小,不值得纳入;第二,基于时间偏好对抗菌药物耐药性成本进行了隐性贴现,使得成本过小,不值得纳入;第三,基于不确定性对抗菌药物耐药性成本进行了隐性贴现,使得成本过小,不值得纳入;第四,成本难以衡量。尽管排除抗菌药物耐药性成本似乎没有方法上的正当理由,但由于衡量这些成本存在实际困难,它们似乎很可能会继续被忽视。本文最后讨论了用于应对福利经济学其他领域外部效应的标准政策措施的适用性。